umbilical cord-derived mesenchymal stem cells + conventional treatment

This combination therapy consists of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered alongside standard conventional treatment for liver cirrhosis. Developed and studied at Beijing 302 Hospital (also known as the Research Center for Biological Therapy or The Institute of Translational Hepatology), the UC-MSCs are derived from human umbilical cord Wharton's jelly and prepared in a GMP-compliant facility. The cells are administered intravenously, typically at doses of 0.5-1.0×10^6 cells/kg body weight, given three times at 4-week intervals. The therapy is primarily investigated for decompensated liver cirrhosis, particularly HBV-related cases, and primary biliary cirrhosis. UC-MSCs are believed to exert therapeutic effects through immune regulation and tissue regeneration, potentially reducing hepatic inflammation and promoting the repair of damaged liver architecture. Clinical trials, including Phase 1/2 studies (NCT01220492), have demonstrated that this combination approach can improve liver function and overall survival rates compared to conventional treatment alone.

Other names

conventional plus MSC treatmentUC-MSC treatmentumbilical cord-derived mesenchymal stem cells